These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8516812)

  • 21. Pharmacological profile of TCV-309--a potent PAF antagonist.
    Terashita Z; Takatani M; Nishikawa K
    J Lipid Mediat; 1992; 5(2):183-5. PubMed ID: 1445598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of the platelet-activating factor inhibitor TCV-309 on reperfusion injury in a canine model of ischemic lung.
    Kawahara K; Tagawa T; Takahashi T; Akamine S; Nakamura A; Yamamoto S; Muraoka S; Tomita M
    Transplantation; 1993 Jun; 55(6):1438-9. PubMed ID: 8516834
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of prostaglandin of E, F and I series, leukotriene C and platelet activating factor on amylase release from isolated rat pancreatic acini.
    Jaworek J; Konturek SJ
    J Physiol Pharmacol; 1993 Dec; 44(4):365-81. PubMed ID: 7510150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of inflammatory mediators in the mechanism of the host immune response induced by ischemia-reperfusion injury.
    Nikbakht-Sangari M; Qayumi AK; Keown PA
    Immunol Invest; 2000 Feb; 29(1):13-26. PubMed ID: 10709843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Donor administration of PAF antagonist (TCV-309) enhances lung preservation.
    Ide S; Kawahara K; Takahashi T; Sasaki N; Shingu H; Nagayasu T; Yamamoto S; Tagawa T; Tomita M
    Transplant Proc; 1995 Feb; 27(1):570-3. PubMed ID: 7879103
    [No Abstract]   [Full Text] [Related]  

  • 26. Therapeutic potential of platelet-activating factor antagonism in the management of myocardial infarction.
    Loucks EB; Qayumi AK; Godin DV; English JC; Lim SP; Al Mahmeed T; Gul S
    Can J Cardiol; 2000 Apr; 16(4):497-504. PubMed ID: 10787465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of platelet-activating factor in regional myocardial ischemia-reperfusion injury.
    Qayumi AK; English JC; Godin DV; Ansley DM; Loucks EB; Lee JU; Kim CW
    Ann Thorac Surg; 1998 Jun; 65(6):1690-7. PubMed ID: 9647083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of platelet-activating factor antagonist E5880 on intrahepatic and systemic metabolic responses to transient hepatic inflow occlusion and reperfusion in the rabbit.
    Nakatani T; Sakamoto Y; Ando H; Kobayashi K
    World J Surg; 1996 Oct; 20(8):1060-7; discussion 1067-8. PubMed ID: 8798365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The beneficial effect of a prostaglandin I2 analog on ischemic rat liver.
    Suzuki S; Nakamura S; Koizumi T; Sakaguchi S; Baba S; Muro H; Fujise Y
    Transplantation; 1991 Dec; 52(6):979-83. PubMed ID: 1750084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of TCV-309, a novel platelet activating factor antagonist, on hemodynamics in dogs with endotoxin-induced shock.
    Okano S; Tagawa M; Urakawa N
    J Vet Med Sci; 1995 Apr; 57(2):385-7. PubMed ID: 7492672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of platelet-activating factor on extravascular lung water after coronary reperfusion in dogs.
    Izuoka T; Takayama Y; Sugiura T; Taniguchi H; Tamura T; Kitashiro S; Jikuhara T; Iwasaka T
    Jpn J Physiol; 1998 Apr; 48(2):157-61. PubMed ID: 9639551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of platelet activating factor antagonist (TCV-309) on lung injury in dogs with experimentally endotoxin-induced shock.
    Okano S; Tagawa M; Urakawa N
    J Vet Med Sci; 1995 Aug; 57(4):751-3. PubMed ID: 8519912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of TCV-309, a novel PAF antagonist, on circulatory shock and hematological abnormality induced by endotoxin in dogs.
    Kawamura M; Kitayoshi T; Terashita Z; Fujiwara S; Takatani M; Nishikawa K
    J Lipid Mediat Cell Signal; 1994 May; 9(3):255-65. PubMed ID: 7921785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of PGI2 analog in preventing ischemia reperfusion damage of liver grafts from living donors.
    Goto S; Kim YI; Kawano K; Kai T; Kobayashi M
    Transpl Int; 1992; 5 Suppl 1():S366-9. PubMed ID: 14621823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. N-acetylcysteine ameliorates reperfusion injury after warm hepatic ischemia.
    Fukuzawa K; Emre S; Senyuz O; Acarli K; Schwartz ME; Miller CM
    Transplantation; 1995 Jan; 59(1):6-9. PubMed ID: 7839430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platelet activating factor (PAF) antagonists: development of a highly potent PAF antagonist, TCV-309.
    Takatani M; Maezaki N; Imura Y; Terashita Z; Nishikawa K; Tsushima S
    Adv Prostaglandin Thromboxane Leukot Res; 1991; 21B():943-6. PubMed ID: 1825438
    [No Abstract]   [Full Text] [Related]  

  • 37. Protective effect of platelet-activating factor antagonist on ischemia-induced liver injury in rats.
    Wang KS; Monden M; Kanai T; Gotoh M; Umeshita K; Ukei T; Mori T
    Surgery; 1993 Jan; 113(1):76-83. PubMed ID: 8417492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased prostaglandin I2 and thromboxane A2 production by rat dental pulp after intravenous administration of endotoxin.
    Hirafuji M; Shinoda H
    Arch Oral Biol; 1994 Nov; 39(11):995-1000. PubMed ID: 7695514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiac functional and structural alterations induced by endotoxin in rats: importance of platelet-activating factor.
    Iwase M; Yokota M; Kitaichi K; Wang L; Takagi K; Nagasaka T; Izawa H; Hasegawa T
    Crit Care Med; 2001 Mar; 29(3):609-17. PubMed ID: 11373429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of platelet activating factor on severity of ischemic colitis.
    Nagahata Y; Azumi Y; Akimoto T; Nomura H; Ichihara T; Idei H; Kuroda Y
    Dis Colon Rectum; 1999 Feb; 42(2):218-24. PubMed ID: 10211499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.